BioCryst Pharmaceuticals’ (BCRX) “Buy” Rating Reiterated at HC Wainwright

BioCryst Pharmaceuticals (NASDAQ:BCRX)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They currently have a $30.00 target price on the biotechnology company’s stock. HC Wainwright’s target price points to a potential upside of 488.24% from the stock’s current price. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ FY2028 earnings at $1.31 EPS.

Separately, Needham & Company LLC restated a “buy” rating and issued a $12.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, April 10th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $14.00.

BioCryst Pharmaceuticals Trading Down 3.0 %

Shares of NASDAQ BCRX opened at $5.10 on Tuesday. BioCryst Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $8.96. The stock has a market cap of $1.05 billion, a P/E ratio of -4.77 and a beta of 1.96. The business’s fifty day simple moving average is $4.89 and its 200-day simple moving average is $5.45.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The business had revenue of $92.80 million during the quarter, compared to analyst estimates of $85.62 million. During the same quarter in the prior year, the business earned ($0.28) earnings per share. The firm’s quarterly revenue was up 34.9% on a year-over-year basis. On average, equities analysts forecast that BioCryst Pharmaceuticals will post -0.69 EPS for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in BCRX. Braidwell LP increased its position in shares of BioCryst Pharmaceuticals by 92.1% during the third quarter. Braidwell LP now owns 5,362,980 shares of the biotechnology company’s stock worth $37,970,000 after purchasing an additional 2,571,100 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of BioCryst Pharmaceuticals by 15.4% during the fourth quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company’s stock worth $106,405,000 after buying an additional 2,371,401 shares during the last quarter. Norges Bank purchased a new position in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $13,278,000. Deerfield Management Company L.P. Series C grew its holdings in shares of BioCryst Pharmaceuticals by 148.6% during the third quarter. Deerfield Management Company L.P. Series C now owns 3,286,000 shares of the biotechnology company’s stock worth $23,265,000 after buying an additional 1,964,000 shares during the last quarter. Finally, Avoro Capital Advisors LLC grew its holdings in shares of BioCryst Pharmaceuticals by 13.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 13,050,000 shares of the biotechnology company’s stock worth $78,170,000 after buying an additional 1,500,000 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.